In contrast, TIGIT and CD96 are inhibitory receptors, and PVR upregulation in heterogeneous tumor cells results in tumor cell recognition and binding by activating receptor CD226 and the inhibitory receptors TIGIT and CD96 [27]. This evidence concerns the gene CD96 and neoplasm.